Novonesis Acquires MicroBioGen to Strengthen Yeast Capabilities

Novonesis, a leading pure-play biology company, has completed the acquisition of MicroBioGen, an Australian biotechnology company with a proven track record in bioethanol and a range of other industrial applications. The acquisition, which follows Novonesis’ investment in MicroBioGen in 2013 and its existing 23% ownership stake, further strengthens a collaboration that has spanned more than a decade.

The acquisition of MicroBioGen adds advanced yeast-breeding expertise to Novonesis, complementing the company’s existing scientific foundation in microbiology and industrial fermentation. This move builds on Novonesis’ commitment to its 2030 strategy, with the acquisition expected to unlock broader potential across multiple industries.

MicroBioGen’s advanced yeast-breeding capabilities will now be integrated into Novonesis, allowing the company to develop new biosolutions for customers across various industries. The acquisition reflects Novonesis’ disciplined approach to investing for growth, with the company aiming to further strengthen its yeast capabilities and continue developing the biosolutions its customers need.

MicroBioGen has been a highly valued partner for more than a decade, and the acquisition marks the next step in their collaborative journey. By combining their complementary expertise and technologies, Novonesis and MicroBioGen can further enhance their yeast capabilities and explore applications beyond bioethanol, including those in other industries.

Novonesis will continue to support MicroBioGen’s existing partners and ensure continuity in its collaborations. The acquisition of MicroBioGen is expected to have a significant impact on Novonesis’ future growth and innovation, positioning the company to meet the evolving needs of its customers and contribute to the broader industry landscape.

Novonesis, a pure-play biology company, has completed the acquisition of MicroBioGen, an Australian biotechnology company with a proven track record in bioethanol and a range of other industrial applications. The acquisition, which follows Novonesis’ investment in MicroBioGen in 2013 and its existing 23% ownership stake, further strengthens a collaboration that has spanned more than a decade. The acquisition of MicroBioGen adds advanced yeast-breeding expertise to Novonesis, complementing the company’s existing scientific foundation in microbiology and industrial fermentation. This move builds on Novonesis’ commitment to its 2030 strategy, with the acquisition expected to unlock broader potential across multiple industries. MicroBioGen’s advanced yeast-breeding capabilities will now be integrated into Novonesis, allowing the company to develop new biosolutions for customers across various industries. The acquisition reflects Novonesis’ disciplined approach to investing for growth, with the company aiming to further strengthen its yeast capabilities and continue developing the biosolutions its customers need. MicroBioGen has been a highly valued partner for more than a decade, and the acquisition marks the next step in their collaborative journey. By combining their complementary expertise and technologies, Novonesis and MicroBioGen can further enhance their yeast capabilities and explore applications beyond bioethanol, including those in other industries. Novonesis will continue to support MicroBioGen’s existing partners and ensure continuity in its collaborations. The acquisition of MicroBioGen is expected to have a significant impact on Novonesis’ future growth and innovation, positioning the company to meet the evolving needs of its customers and contribute to the broader industry landscape.